Axogen, Inc. reported strong financial results for the second quarter of 2025, with revenue reaching $56.7 million, a significant increase from the previous year. The company also saw improvements in gross margin, net income, and adjusted EBITDA. Cash and cash equivalents increased to $35.9 million by June 30, 2025.

CEO Michael Dale expressed satisfaction with the revenue growth and market development strategies, emphasizing the company’s commitment to advancing nerve repair solutions. Business highlights included double-digit revenue growth across all markets, expanded coverage for nerve repair, and key regulatory milestones achieved in the second quarter of 2025.

Axogen raised its revenue guidance for 2025 to at least 17% growth, targeting $219 million for the year. The company expects gross margin to be between 73% and 75%, factoring in costs related to the anticipated approval of the Avance® Nerve Graft BLA. Axogen remains confident in achieving net cash flow positivity for the full year.

Investors can join Axogen’s conference call today at 8:00 a.m. ET to learn more about the company’s financial performance and strategic outlook. The call can be accessed by phone or online through the Investors page of Axogen’s website. A replay will also be available on the website following the conference call.

Axogen is a leading company focused on developing technologies for peripheral nerve regeneration and repair. Their innovative products, such as Avance® Nerve Graft and Axoguard Nerve Connector®, provide solutions for patients with peripheral nerve injuries. The company’s portfolio is available in several countries, aiming to improve quality of life for those affected by nerve damage.

Read more at GlobeNewswire: Axogen, Inc. Reports Second Quarter 2025 Financial Results